Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma
โ Scribed by Shigeharu Fujieda; Koutetsu Lee; Hiroshi Sunaga; Hideaki Tsuzuki; Hideki Ikawa; Guo-Kang Fan; Masashi Imanaka; Hiroshi Takenaka; Hitoshi Saito
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 494 KB
- Volume
- 85
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
BACKGROUND. Interleukin-10 (IL-10) has been implicated as an important modulator of lymphoid cells, and its sequence is homologous to an open reading frame in the Epstein-Barr virus (EBV) genome. Nasopharyngeal carcinoma (NPC) is a representative tumor related to EBV infection.
METHODS.
The authors investigated the expression of IL-10 in 21 primary NPCs by using an immunohistochemical approach to examine its prognostic significance.
Results
. IL-10 staining was positive in 12 of 21 primary NPCs (57%). There was no association between IL-10 expression and gender, tumor size, the occurrence of lymph node metastases, clinical stage, or recurrence. However, there was a significant difference in overall survival between the negative expression and positive expression of IL-10 (P ฯญ 0.0348). Although 87.5% of the IL-10 negative group survived for 5 years, only 15.6% of IL-10 positive patients survived for that length of time by the Kaplan-Meier method. IL-10 expression was significant as an independent prognostic indicator of overall survival by multivariate analysis using the Cox proportional hazards model (odds ratio, 26.64; P ฯญ 0.0019).
CONCLUSIONS.
The results imply that expression of IL-10 is a prognostic factor in patients with NPC and may prove valuable in selecting patients with NPC who are candidates for aggressive therapy.
๐ SIMILAR VOLUMES
Background and Objectives: Limb reconstruction after total scapulectomy for malignant bone and soft-tissue tumors around the scapula is difficult. This study was undertaken to clarify the clinical results of total scapulectomy in patients with malignant bone and soft-tissue tumors around the shoulde